Publications
Search our bibliography using the filters on the right-hand side.
Displaying 51 through 100 of 275 publications.
Skip to main content
Yee K, Chirila C, Davenport E, Mladsi D, Barnett C, Kronenberger WG. Using projected retained ability score to assess cognitive development in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT. Poster presented at the 2021 ACMG Annual Clinical Genetics Virtual Meeting; April 2021.
Samuelson TW, Singh IP, Williamson BK, Falvey H, Lee WC, Odom D, McSorley D, Katz LJ. Quality of life in primary open-angle glaucoma and cataract: an analysis of VFQ-25 and OSDI from the iStent inject® Pivotal Trial. Am J Ophthalmol. 2021 Mar 15;229:220-9. doi: 10.1016/j.ajo.2021.03.007
Baraliakos X, Van den Bosch F, Machado PM, Gensler LS, Marzo-Ortega H, Sherif B, Quebe-Fehling E, Porter B, Gaillez C, Deodhar A. Achievement of remission endpoints with secukinumab over 3 years in active ankylosing spondylitis: pooled analysis of two phase 3 studies. Rheum Ther. 2021 Mar;8(1):273-88. doi: 10.1007/s40744-020-00269-6
Wyrwicz L, Elimova E, Blum SI, Xiao H, Davenport E, Wang J, Hunter S, Li M, Kondo K, Mohler M. Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): interim results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649. Poster presented at the 2021 ASCO Conference; June 4, 2021. [abstract] J Clin Oncol. 2021; 39(Suppl 15):4066. doi: 10.1200/JCO.2021.39.15_suppl.4066
Stull K, Patil D, Gomez B, Feldman SR. Correlation between change in psoriasis area and severity index and dermatology life quality index in patients with psoriasis: pooled analysis from four phase III clinical trials. Poster presented at the 2020 Virtual 29th European Academy of Dermatology and Venerology Congress; October 28, 2020.
Hunter S, Garbinsky D, La EM, Poston S, Hogea C. Impact of state of residence on adult vaccination uptake: a multilevel modeling approach. Presented at the IDWeek 2020 Virtual Conference; October 21, 2020.
Reed S, Getahun D, Gatz J, Armstrong M, Raine-Bennett T, Zhou X, Fassett M, Peipert J, Saltus CW, Im T, Alabaster A, Hunter S, Takhar H, Chillemi G, Xie F, Wang J, Chiu V, Frenz A, Shi J, Lynen R, Asiimwe A, Anthony MS. Postpartum timing of IUD insertion is associated with risk of uterine perforation: results from APEX IUD. Poster presented at the Society of Family Planning Virtual 2020 Annual Meeting; October 9, 2020. [abstract] Contraception. 2020 Oct; 102(4):302. doi: 10.1016/j.contraception.2020.07.099
Raine-Bennett TR, Gatz JL, Reed SD, Armstrong MA, Getahun D, Zhou X, Merchant M, Takhar HS, Ichikawa LE, Peipert JF, Saltus CW, Fassett MJ, Chillemi GA, Im TM, Lynen R, Shi JM, Wang J, Xie F, Hunter S, Chiu VY, Asiimwe A, Anthony MS. Postpartum timing of IUD insertion is associated with risk of IUD expulsion: results from APEX IUD. Poster presented at the Society of Family Planning Virtual 2020 Annual Meeting; October 9, 2020. [abstract] Contraception. 2020 Oct; 102(4):295-6.
Reed SD, Armstrong MA, Getahun D, Gatz JL, Raine-Bennett TR, Alabaster AL, Ichikawa L, Saltus CW, Xie F, Zhou X, Fassett MJ, Peipert JF, Merchant M, Chiu VY, Hunter S, Schoendorf J, Shi JM, Chillemi GA, Im TM, Takhar HS, Asiimwe A, Anthony MS. Risk of uterine perforation and expulsion associated with breastfeeding among postpartum women with an intrauterine device insertion: results from APEX IUD. Poster presented at the Society of Family Planning Virtual 2020 Annual Meeting; October 9, 2020. [abstract] Contraception. 2020 Oct; 102(4):297.
Ritchey ME, Gatz J, Merchant M, Fassett M, Reed S, Saltus C, Getahun D, Peipert J, Chillemi G, Bartsch J, Im T, Asiimwe A, Armstrong MA, Anthony M. Risk across postpartum timing of insertion in women with intrauterine devices. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Ritchey ME, Reed S, Alabaster A, Getahun D, Gatz J, Saltus C, Amstrong MA, Xie F, Wang J, Fassett M, Chillemi G, Peipert J, Hunter S, Ichikawa L, Asiimwe A, Anthony M. Are indicators of difficult insertion among women with intrauterine devices associated with uterine perforation and expulsion? Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Saltus C, Reed S, Peipert J, Fassett M, Merchant M, Asiimwe A, Ritchey ME, Xie F, Amstrong MA, Gatz N, Ichikawa L, Getahun D, Lynen R, Wang J, Hunter S, Chillemi G, Anthony M. IUD type and indicators of difficult insertion among women with intrauterine devices. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Saltus C, Asiimwe A, Peipert J, Reed S, Getahun D, Alabaster A, Ritchey ME, Ichikawa L, Gatz J, Chiu V, Merchant M, Fassett M, Frenz A-K, Armstrong MA, Wang J, Hunter S, Chillemi G, Anthony M. Assessing outcomes of uterine perforation and IUD expulsion before and after ICD-9-CM to ICD-10-CM transition in women with IUD insertions. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Anthony M, Getahun D, Amstrong MA, Gatz J, Asiimwe A, Saltus C, Reed S, Shi J, Alabaster A, Fassett M, Peipert J, Schoendorf J, Hunter S, Wang J, Chillemi G, Ritchey ME. Breastfeeding, postpartum timing, and indicators of difficult insertion among women with intrauterine devices. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Reed SD, Saltus CW, Getahun D, Schoendorf J, Armstrong MA, Peipert JF, Raine-Bennett TR, Ritchey ME, Ichikawa LE, Zhou X, Fassett MJ, Alabaster A, Xie F, Merchant M, Chiu VY, Shi JM, Frenz A-K, Im TM, Takhar HS, Lynen R, Asiimwe A, Anthony MS. Menorrhagia and risk of intrauterine device (IUD) expulsion and uterine perforation: results from the APEX IUD study. Presented at the Virtual 76th Scientific Congress of the American Society for Reproductive Medicine (ASRM); October 17, 2020. [abstract] Fertil Steril. 2020 Sep 1; 114(3 Suppl):e12. doi: 10.1016/j.fertnstert.2020.08.059
Zhou X, Garbinsky D, Ouyang J, Davenport E, Agarwal I, Oberdhan D. Longitudinal data on treatment duration and compliance from autosomal dominant polycystic kidney disease clinical trials with tolvaptan. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa139.S. doi: 10.1093/ndt/gfaa139.SO093
Zhou X, Davenport E, Ouyang J, Hoke M, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across an expanded pooled database of multiple autosomal dominant polycystic kidney disease clinical studies. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa142.P. doi: 10.1093/ndt/gfaa142.P0037
Zhou X, Davenport EK, Ouyang J, Krasa H, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across a pooled database of multiple Autosomal Dominant Polycystic Kidney Disease (ADPKD) clinical studies. Poster presented at the 2020 National Kidney Foundation Spring Clinical Meeting; March 2020. New Orleans, LA. [abstract] Am J Kidney Dis. 2020 Apr; 75(4):663.
Samuelson T, Singh IP, Katz LJ, Falvey H, Odom D, McSorley D. Effect of iStent inject trabecular micro-bypass on patient-reported outcomes for those with open-angle glaucoma and coexisting cataracts. Poster presented at the ISPOR 2019 European Conference; November 6, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).
Saltus CW, Gatz J, Ritchey ME, Ichikawa LE, Armstrong MA, Alabster AL, Merchant M, Lynen R, Asiimwe A, Shi JM, Getahun DT, Xie F, Chiu VY, Anthony MS. Study of the association of uterine perforation and IUD expulsion with breastfeeding and postpartum timing at IUD insertion (APEX IUD) - study size estimation to actuality. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):748. doi: 10.1002/pds.4864
Himmler S, Mueller M, Sherif B, Ostwald D. A case study applying a novel approach to estimate the social impact of a medical innovation - the use of secukinumab for psoriatic arthritis in Germany. Expert Rev Pharmacoecon Outcomes Res. 2019 Jul 29. doi: 10.1080/14737167.2019.1644169
Hofheinz R, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life across three tumor types. Poster presented at the 2019 ESMO World Congress on Gastrointestinal Cancer Conference; July 2019. Barcelona, Spain.
Houghton K, Stull D, Germino B. A novel analytic modeling approach for linking real-world and clinical trial data. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 22, 2019. New Orleans, LA.
Houghton K, Ainsworth C, Stull D, Haberland C, Filonenko A, Seitz C, Gerlinger C. Exploring variability in patient-reported pain and treatment efficacy in patients with endometriosis. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 20, 2019. New Orleans, LA.
Link BK, Day BM, Zhou X, Zelenetz AD, Dawson KL, Cerhan JR, Flowers CR, Friedberg JW. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol. 2019 Feb;184(4):660-3. doi: 10.1111/bjh.15149
Warren RB, Halliday A, Graham CN, Gilloteau I, Miles L, McBride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2178-84. doi: 10.1111/jdv.15094
Maurer M, Houghton K, Costa C, Dabove F, Ensina LF, Gimenez-Arnau A, Guillet G, Konstantinou GN, Labrador-Horrillo M, Lapeere H, Meshkova R, Pastorello E, Velasquez-Lopera M, Tamayo Quijano LM, Vestergaard C, Chapman-Rothe N. Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study. World Allergy Organ J. 2018 Nov 16;11(32). doi: 10.1186/s40413-018-0216-1
Coates L, Gossec L, Kirkham B, Sherif B, Gaillez C, Mpofu S, Jugl SM, Karyekar C, Gandhi KK. Minimal disease activity among active psoriatic arthritis patients treated with Secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study. Arthritis Care Res (Hoboken). 2018 Oct;70(10):1529-35. doi: 10.1002/acr.23537
Feldman SR, Zhao Y, Gilloteau I, Graham CN, Miles L, McBride D, Herrera V. Higher psoriasis skin clearance is associated with lower annual indirect costs in the United States: a post hoc analysis from the CLEAR Study. J Manag Care Spec Pharm. 2018 Jul;24(7):617-22. doi: 10.18553/jmcp.2018.24.7.617
Stull DE, Griffiths CEM, Gilloteau I, Zhao Y, Guana A, Finlay AY, Sherif B, Houghton K, Puig L. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis. Br J Dermatol. 2018 Jun;178(6):1297-307. doi: 10.1111/bjd.16366
Maurer M, Houghton K, Berroa F, Ensina LF, Guillet G, Labrador M, Gimenez-Arnau AM, Marsland A, Rossi O, Velasco M, Chapman-Rothe N. Angioedema with and without wheals in patients with chronic spontaneous urticaria: findings from the worldwide prospective observational aware study. Presented at the EAACI Congress 2018; May 27, 2018. Munich, Germany.
Donohue IF, Bollu VK, Stull DE, Nelson LM, Williams VS, Stensland MD, Hanania NA. Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. Int J Chron Obstruct Pulmon Dis. 2018 Feb 5;13:499-508.
Warren R, Halliday A, Graham CN, Gilloteau I, Miles L, Sherif B, McBride D. Secukinumab significantly reduces work impairment and indirect costs compared to ustekinumab and etanercept in the United Kingdom. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 8, 2017. Glasgow, Scotland.
Maurer M, Houghton K, Guillet G, Kasujee I, Labrador M, Marsland A, McBride D, Rossi O, Stull DE, Valesco M, Chapman-Rothe N. Quality of life and presence of angioedema among patients with chronic urticaria in Europe: longitudinal findings from the worldwide prospective observational AWARE study. Presented at the 26th EADV Congress; September 16, 2017. Geneva, Switzerland.
Maurer M, Houghton K, Guillet G, Kasujee I, Labrador M, Marsland M, McBride D, Rossi O, Stull DE, Valesco M, Chapman-Rothe N. Quality of life and disease control among patients with chronic urticaria in Europe: longitudinal findings from the worldwide prospective observational AWARE study. Poster presented at the 26th EADV Congress; September 13, 2017. Geneva, Switzerland.
Korman NJ, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Nyirady J, Williams N, Mordin M, Tyring S. Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis. J Dermatolog Trea. 2017 Aug;28(5):384-9.
Maurer M, Berroa F, Castronuovo A, Ensina LF, Guillet G, Kasujee I, Houghton K, Labrador M, Marsland A, McBride D, Rossi O, Valesco M, Stull DE, Chapman-Rothe N. Chronic inducible urticaria (CIndU) in Europe, Central America, and South America: findings from visit 1 of the worldwide AWARE Study. Poster presented at the EAACI Congress 2017; June 20, 2017. Helsinki, Finland.
Maurer M, Guillet G, Houghton K, Kasujee I, Labrador M, Marsland A, McBride D, Rossi O, Stull DE, Valesco M, Chapman-Rothe N. Treatment of patients with chronic urticaria in Europe: findings from visit 1 of the worldwide prospective observational AWARE study. Poster presented at the EAACI Congress 2017; June 19, 2017. Helsinki, Finland.
Maurer M, Berroa F, Castronuovo A, Ensina LF, Guillet G, Kasujee I, Houghton K, Labrador M, Marsland A, McBride D, Rossi O, Valesco M, Stull DE, Chapman-Rothe N. Healthcare resource utilisation due to chronic urticaria in Europe, South America, and Central America: findings from visit 1 of the worldwide AWARE study. Poster presented at the EAACI Congress 2017; June 18, 2017. Helsinki, Finland.
Chirila C, Nuamah I, Woodruff K. Health care resource use analysis of paliperidone palmitate 3 month injection from two phase 3 clinical trials. Curr Med Res Opin. 2017 Jun;33(6):1083-90. doi: 10.1080/03007995.2017.1300144
Boye ME, Houghton K, Stull DE, Ainsworth C, Price GL. Estimating the effects of patient-reported outcome (PRO) diarrhea and pain measures on PRO fatigue: data analysis from a phase 2 study of abemaciclib monotherapy, a CDK4 and CDK6 inhibitor, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic disease: MONARCH 1. Poster presented at the 2017 ASCO Annual Meeting; June 4, 2017. Chicago, IL. [abstract] J Clin Oncol. 2017 Jun; 35(2017).
Stull DE, Houghton K, Ainsworth C, Price G, Boye ME. The effects of disease and treatment-associated cancer symptoms on health-related quality-of-life: the mediating effect of fatigue in non-small cell lung cancer and metastatic breast cancer. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A121.
Puig L, Griffiths CE, Zhou Y, Gilloteau I, Guana A, Houghton K, Stull DE. Differential effects of secukinumab vs. ustekinumab for treatment of moderate to severe psoriasis on work productivity and activity impairment: a structural equation modelling approach using the CLEAR 52-week study. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A161.
Marzo-Ortega H, Halliday A, Jugl S, Mokashi S, Porter B, Talloczy Z, Sherif B, Williams N, Keat A. Impact of alternative definitions of treatment response on long-term efficacy of secukinumab in tumour necrosis factor alpha-naïve patients with active ankylosing spondylitis. Poster presented at the British Society for Rheumatology 2017; April 25, 2017. Birmingham, United Kingdom.
Emery P, Halliday A, Jugl S, Mokashi S, Porter B, Martin R, Sherif B, Williams N, Marzo-Ortega H. Week 12 response predicts long-term efficacy of secukinumab in patients with active ankylosing spondylitis independent of previous TNFi exposure. Poster presented at the British Society for Rheumatology 2017; April 2017. Birmingham, United Kingdom.
Wong-Sefidan I, Byrtek M, Zhou X, Friedberg JW, Flowers CR, Zelenetz AD, Dawson KL, Reid E. Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice. Leuk Lymphoma. 2017 Apr;58(4):809-15.
Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, Fox T, Mordin M, Gnanasakthy A, Papavassilis C, Lebwohl MG. Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. J Am Acad Dermatol. 2017 Apr;76(4):655-61. doi: 10.1016/j.jaad.2016.11.043
Glaser DA, Hebert AA, Fehnel S, DiBenedetti D, Nelson L, Drew J, Pariser DM. The axillary sweating daily diary: a validated patient-reported outcome measure to assess axillary hyperhidrosis symptom severity. Poster presented at the 2017 Maui Derm for Dermatologists; March 2017. Maui, HI.
Feldman S, Zhao Y, Gilloteau I, Graham CN, Miles L, McBride D, Herrera V. Higher psoriasis skin clearance is associated with lower annual indirect costs in the United States. Poster presented at the 2017 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 2017. Denver, CO. [abstract] J Manag Care Spec Pharm. 2017 Mar; 23(3-a):S84.
Odom D, Mladsi D, Purser M, Kaye JA, Palaka E, Charter A, Jensen JA, Sellami D. A matching-adjusted indirect comparison of sonidegib and vismodegib in advanced basal cell carcinoma. J Skin Cancer. 2017;2017:6121760. doi: 10.1155/2017/6121760